Summary
Johnson & Johnson (JNJ) filed an 8-K on October 15, 2019, to report its third-quarter financial results for the period ended September 29, 2019. The filing primarily consists of a press release and supplementary financial data, highlighting the company's sales and earnings performance. Investors should pay close attention to these results as they provide insights into the operational performance and financial health of JNJ's diverse business segments, including Pharmaceuticals, Medical Devices, and Consumer Health. While the specific details of the Q3 2019 performance are contained within the attached press release (Exhibit 99.1) and supplementary data (Exhibit 99.2), the 8-K filing serves as the official notification of these results. Investors can use this information to assess trends, evaluate management's performance against expectations, and make informed investment decisions regarding JNJ's stock.
Key Highlights
- 1JNJ announced its third-quarter 2019 financial results on October 15, 2019.
- 2The filing includes a press release detailing Q3 sales and earnings.
- 3Supplementary sales data and condensed consolidated statements of earnings for Q3 are also provided.
- 4The reported results pertain to the fiscal quarter ended September 29, 2019.
- 5This 8-K filing is a standard regulatory disclosure for reporting quarterly financial performance.
- 6Investors can find detailed operational and financial metrics within the attached exhibits.